Markers of Myocardial Damage Predict Mortality in Patients With Aortic Stenosis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
10 08 2021
Historique:
received: 15 04 2021
revised: 07 05 2021
accepted: 10 05 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 16 12 2021
Statut: ppublish

Résumé

Cardiovascular magnetic resonance (CMR) is increasingly used for risk stratification in aortic stenosis (AS). However, the relative prognostic power of CMR markers and their respective thresholds remains undefined. Using machine learning, the study aimed to identify prognostically important CMR markers in AS and their thresholds of mortality. Patients with severe AS undergoing AVR (n = 440, derivation; n = 359, validation cohort) were prospectively enrolled across 13 international sites (median 3.8 years' follow-up). CMR was performed shortly before surgical or transcatheter AVR. A random survival forest model was built using 29 variables (13 CMR) with post-AVR death as the outcome. There were 52 deaths in the derivation cohort and 51 deaths in the validation cohort. The 4 most predictive CMR markers were extracellular volume fraction, late gadolinium enhancement, indexed left ventricular end-diastolic volume (LVEDVi), and right ventricular ejection fraction. Across the whole cohort and in asymptomatic patients, risk-adjusted predicted mortality increased strongly once extracellular volume fraction exceeded 27%, while late gadolinium enhancement >2% showed persistent high risk. Increased mortality was also observed with both large (LVEDVi >80 mL/m Machine learning identified myocardial fibrosis and biventricular remodeling markers as the top predictors of survival in AS and highlighted their nonlinear association with mortality. These markers may have potential in optimizing the decision of AVR.

Sections du résumé

BACKGROUND
Cardiovascular magnetic resonance (CMR) is increasingly used for risk stratification in aortic stenosis (AS). However, the relative prognostic power of CMR markers and their respective thresholds remains undefined.
OBJECTIVES
Using machine learning, the study aimed to identify prognostically important CMR markers in AS and their thresholds of mortality.
METHODS
Patients with severe AS undergoing AVR (n = 440, derivation; n = 359, validation cohort) were prospectively enrolled across 13 international sites (median 3.8 years' follow-up). CMR was performed shortly before surgical or transcatheter AVR. A random survival forest model was built using 29 variables (13 CMR) with post-AVR death as the outcome.
RESULTS
There were 52 deaths in the derivation cohort and 51 deaths in the validation cohort. The 4 most predictive CMR markers were extracellular volume fraction, late gadolinium enhancement, indexed left ventricular end-diastolic volume (LVEDVi), and right ventricular ejection fraction. Across the whole cohort and in asymptomatic patients, risk-adjusted predicted mortality increased strongly once extracellular volume fraction exceeded 27%, while late gadolinium enhancement >2% showed persistent high risk. Increased mortality was also observed with both large (LVEDVi >80 mL/m
CONCLUSIONS
Machine learning identified myocardial fibrosis and biventricular remodeling markers as the top predictors of survival in AS and highlighted their nonlinear association with mortality. These markers may have potential in optimizing the decision of AVR.

Identifiants

pubmed: 34353531
pii: S0735-1097(21)05318-3
doi: 10.1016/j.jacc.2021.05.047
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-558

Subventions

Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/14/78/31020
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/19/35/34374
Pays : United Kingdom
Organisme : British Heart Foundation
ID : SP/20/2/34841
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Crown Copyright © 2021. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Funding Support and Author Disclosures The work was supported by a National Research Foundation of Korea grant funded by the Korea government (Ministry of Science and ICT; No. 2019R1A2C2084099) and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number HI18C2383). The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Soongu Kwak (S)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Russell J Everett (RJ)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Thomas A Treibel (TA)

Barts Health NHS Trust and University College London, London, United Kingdom.

Seokhun Yang (S)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Doyeon Hwang (D)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Taehoon Ko (T)

Office of Hospital Information, Seoul National University Hospital, Seoul, Korea.

Michelle C Williams (MC)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Rong Bing (R)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Trisha Singh (T)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Shruti Joshi (S)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Heesun Lee (H)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Whal Lee (W)

Department of Radiology, Seoul National University Hospital, Seoul, Korea.

Yong-Jin Kim (YJ)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

Calvin W L Chin (CWL)

National Heart Center Singapore, Singapore.

Miho Fukui (M)

Cardiovascular Imaging Research Center and Core Lab, Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, USA.

Tarique Al Musa (T)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Marzia Rigolli (M)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Anvesha Singh (A)

Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.

Lionel Tastet (L)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

Laura E Dobson (LE)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

Stephanie Wiesemann (S)

Charité Campus Buch ECRC and Helios Clinics Cardiology Germany, DZHK partner site, Berlin, Germany.

Vanessa M Ferreira (VM)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Gabriella Captur (G)

Inherited Heart Muscle Disease Clinic, Department of Cardiology, Royal Free Hospital, NHS Foundation Trust, London, United Kingdom.

Sahmin Lee (S)

Division of Cardiology, Asan Medical Center Heart Institute, University of Ulsan College of Medicine, Seoul, South Korea.

Jeanette Schulz-Menger (J)

Charité Campus Buch ECRC and Helios Clinics Cardiology Germany, DZHK partner site, Berlin, Germany.

Erik B Schelbert (EB)

UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Marie-Annick Clavel (MA)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

Sung-Ji Park (SJ)

Division of Cardiology, Department of Medicine, Cardiovascular Imaging Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

Tobias Rheude (T)

Department of Cardiology, German Heart Center Munich, Munich, Germany.

Martin Hadamitzky (M)

Department of Radiology and Nuclear Medicine, German Heart Center Munich, Munich, Germany.

Bernhard L Gerber (BL)

Division of Cardiology, Department of Cardiovascular Diseases, Cliniques Universitaires St. Luc and Institut de Recherche Cardiovasculaire, Université Catholique de Louvain, Brussels, Belgium.

David E Newby (DE)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.

Saul G Myerson (SG)

University of Oxford Centre for Clinical Magnetic Resonance Research, BHF Centre of Research Excellence (Oxford), NIHR Biomedical Research Centre (Oxford), Oxford, United Kingdom.

Phillipe Pibarot (P)

Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart and Lung Institute, Université Laval, Québec City, Québec, Canada.

João L Cavalcante (JL)

UPMC Cardiovascular Magnetic Resonance Center, Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

Gerry P McCann (GP)

Department of Cardiovascular Sciences, Glenfield Hospital, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, United Kingdom.

John P Greenwood (JP)

Multidisciplinary Cardiovascular Research Centre & The Division of Biomedical Imaging, Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, United Kingdom.

James C Moon (JC)

Barts Health NHS Trust and University College London, London, United Kingdom.

Marc R Dweck (MR)

British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: marc.dweck@ed.ac.uk.

Seung-Pyo Lee (SP)

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; Center for Precision Medicine, Seoul National University Hospital, Seoul, South Korea. Electronic address: sproll1@snu.ac.kr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH